Pancreatic neuroendocrine tumor risk factors and prognosis
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study looks at how pancreatic neuroendocrine tumors behave differently in younger versus older people. It aims to find better ways to predict outcomes and guide treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have a confirmed diagnosis of pancreatic neuroendocrine tumor from a biopsy or surgery.
- You cannot have a more aggressive type called pancreatic neuroendocrine carcinoma.
- You must have complete medical records available.
- You cannot have received any cancer treatment before this study.
- You cannot have any other current or past cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of two chemotherapy drugs after surgery can reduce the chance that your pancreatic neuroendocrine tumor comes back. It is for people who have had their tumor completely removed but have a higher risk of recurrence.
This study examines how doctors treat gastroenteropancreatic neuroendocrine tumors (rare slow-growing cancers of the stomach, pancreas, or intestines) and how patients respond. Researchers will review medical records from 2018–2025 to understand which treatments work best and help improve care for future patients.
This trial tests whether surgically removing as much of the tumor as possible (debulking) is better than not doing surgery for people with advanced pancreatic neuroendocrine tumors. It aims to see if this approach can improve outcomes.
This study offers genetic (inherited) testing for people with pancreatic neuroendocrine neoplasms. The goal is to see who may have a genetic predisposition, which can help guide medical care and family risk.
This Phase 2 trial studies whether giving chemotherapy after surgery can lower cancer recurrence risk in people with high-risk pancreatic neuroendocrine tumors (NETs). It may help you by testing an added treatment after the tumor has been removed.
This study looks at the nutritional health of people with a type of digestive tumor called a neuroendocrine tumor. It aims to understand how these tumors affect nutrition, which could help doctors improve care.
Hear when a new Pancreatic Neuroendocine Neoplasms (pNETs) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.